NCT03656068View on ClinicalTrials.gov

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 4, 2018

Primary Completion Date

November 25, 2020

Study Completion Date

November 25, 2020

Conditions
Non-alcoholic SteatohepatitisFatty LiverFibrosis, LiverCompensated Cirrhosis
Interventions
DRUG

Nitazoxanide 500mg BID

Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks

Trial Locations (1)

78229

Pinnacle Clinical Research, San Antonio

Sponsors
All Listed Sponsors
lead

Pinnacle Clinical Research, PLLC

OTHER

NCT03656068 - An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis | Biotech Hunter | Biotech Hunter